SPE Capital-led consortium invests in Egypt’s Orchidia Pharmaceutical Industries
Orchidia, founded in 1993, manufactures eye-care medicines for Egypt and export markets across the region.
** For the best experience, download the free Africa Private Equity News app Android | iOS **
A consortium led by SPE Capital has completed an investment in Orchidia Pharmaceutical Industries, an Egyptian manufacturer of eye-care medicines.
The investment was made through SPE Capital’s Private Equity Fund III and includes the European Bank for Reconstruction and Development, Proparco, the French development finance institution, and the Belgian Investment Company for Developing Countries.
Founded in 1993 by Dr Ossama Abbas, Orchidia manufactures ophthalmic pharmaceutical products for Egypt and markets across the Middle East and Africa. Operating through a European holding company, it exports to more than 20 countries.
The deal marks SPE Capital’s second investment partnership with the Abbas family. The private equity firm previously invested in Orchidia between 2013 and 2017 through another fund it managed.
Want to know who is raising, investing, and exiting in Africa? Get Africa Private Equity News’ monthly Dealmaker’s Log – a database of reported investment deals, exits, and fundraising closes. Subscribe now